Drug repurposing opportunities for chronic kidney disease

• Published in: iScience Vol. 27; no. 6; p. 109953
• Main Authors: Chen, Xiong, Shen, Runnan, Zhu, Dongxi, Luo, Shulu, You, Guochang, Li, Ruijie, Hong, Xiaosi, Li, Ruijun, Wu, Jihao, Huang, Yinong, Lin, Tianxin
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 21.06.2024; Elsevier
• Subjects: Bioinformatics; Bioinformatics
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2024.109953

The development of targeted drugs for the early prevention and management of chronic kidney disease (CKD) is of great importance. However, the success rates and cost-effectiveness of traditional drug development approaches are extremely low. Utilizing large sample genome-wide association study data for drug repurposing has shown promise in many diseases but has not yet been explored in CKD. Herein, we investigated actionable druggable targets to improve renal function using large-scale Mendelian randomization and colocalization analyses. We combined two population-scale independent genetic datasets and validated findings with cell-type-dependent eQTL data of kidney tubular and glomerular samples. We ultimately prioritized two drug targets, opioid receptor-like 1 and F12, with potential genetic support for restoring renal function and subsequent treatment of CKD. Our findings explore the potential pathological mechanisms of CKD, bridge the gap between the molecular mechanisms of pathogenesis and clinical intervention, and provide new strategies in future clinical trials of CKD. [Display omitted] •Druggable Mendelian randomization for chronic kidney disease was performed•Opioid receptor-like 1 has potential to restore renal function•F12 has potential to restore renal function Bioinformatics